Read more about the article DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.

DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.

Continue ReadingDNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.
Read more about the article Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre- IND (505(b)(2) submission; Target price remains unchanged.

Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre- IND (505(b)(2) submission; Target price remains unchanged.

Continue ReadingEntera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre- IND (505(b)(2) submission; Target price remains unchanged.
Read more about the article Entera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.

Entera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.

Continue ReadingEntera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.
Read more about the article DNA Biomedical Solutions Ltd. Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre-IND (505(b)(2) submission; Target price remains unchanged.

DNA Biomedical Solutions Ltd. Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre-IND (505(b)(2) submission; Target price remains unchanged.

Continue ReadingDNA Biomedical Solutions Ltd. Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre-IND (505(b)(2) submission; Target price remains unchanged.
Read more about the article DNA Biomedical Solutions Ltd.: Preparations for pre-IND (505(b) (2) submission and expected capital raising by Entera; BeamMed retains a similar sales rate with a growing presence in the US; Target price remains unchanged.

DNA Biomedical Solutions Ltd.: Preparations for pre-IND (505(b) (2) submission and expected capital raising by Entera; BeamMed retains a similar sales rate with a growing presence in the US; Target price remains unchanged.

Continue ReadingDNA Biomedical Solutions Ltd.: Preparations for pre-IND (505(b) (2) submission and expected capital raising by Entera; BeamMed retains a similar sales rate with a growing presence in the US; Target price remains unchanged.